Newsroom | 5442 results

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced new publications on long-term weight loss results with the Allurion Program. In the first study, 522 patients treated with the Allurion Program across nine international obesity centers reduced their weight, on average, by 14.4kg (32lbs) or 13.9% of total body weight in just four months. One year later, the average weight loss was 13.9kg (31lbs) or 13.2% of t...

SANDWICH, U.K.--(BUSINESS WIRE)--Logical Biological launches sister company, Logical Antigen, delivering high-quality antigens and biologicals for in vitro diagnostic market....

BONITA SPRINGS, Fla.--(BUSINESS WIRE)--ARMRA®, the physician-founded wellness brand pioneering whole-body vitality through the power of bovine colostrum, has launched at Ulta Beauty in stores nationwide and online, establishing itself as the first colostrum-based ingestible within the retailer’s wellness assortment. This pivotal partnership with the nation’s largest beauty retailer introduces ARMRA® into The Wellness Shop at Ulta Beauty – a curated destination dedicated to self-care and holisti...

CHICAGO--(BUSINESS WIRE)--Cresco Labs Announces Strategic Restructuring and Plans to Divest California Operations...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi, part of the global healthcare company Fresenius, and a leading provider of essential medicines and medical technologies, announced today it has received the 2025 Supplier Legacy Award from Premier, Inc., a leading technology-driven healthcare performance improvement company. This marks the fifth time since 2015 Premier has recognized Fresenius Kabi USA with this award for operational excellence. Fresenius Kabi was recognized for its long-stand...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency (“MHRA”) to commence EMBRACE, the second pivotal study in PARADIGM, the Company’s Phase 3 multinational program evaluating CYB0...

CHICAGO--(BUSINESS WIRE)--CRESCO LABS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON AUGUST 7, 2025...

SASKATOON, Saskatchewan--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the “Company”) (TSXV: ZYUS), a clinical-stage life sciences company focused on the development and commercialization of novel non-opioid drug candidates for pain management, today announced the appointment of Dr. Julie Stakiw, MD, FRCPC, to the Company’s leadership team as Chief Medical Officer (“CMO”), effective July 14, 2025. Dr. Stakiw is a prominent hematologist-oncologist with over two decades of clinical and academi...

NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to six newly hired non-executive employees consisting of options to purchase an aggregate of 96,400 common shares of the Company (the "Options"), with effective grant dates of July 7, 2025 and July 14, 2025, depending on the applic...

LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through NutriDrip. Rob Fried, CEO of Niagen Bioscience, remarked, “Our partnership with Equinox Hotel and NutriDrip underscores our c...